Status:
ENROLLING_BY_INVITATION
MR Elastography of Cognitive Impairment
Lead Sponsor:
Mayo Clinic
Collaborating Sponsors:
National Institute on Aging (NIA)
Conditions:
Alzheimer Disease
Mild Cognitive Impairment
Eligibility:
All Genders
18-100 years
Brief Summary
The purpose of this research is to further investigate the potential of brain stiffness as a novel biomarker for Alzheimer's disease.
Detailed Description
Due to shifting demographics, the prevalence of dementia continues to increase in the population. To mitigate the effects of dementia will require new treatments working jointly with new methods for e...
Eligibility Criteria
Inclusion
- Inclusion Criteria for Control Subjects:
- In good general health
- No Active neurological or psychiatric conditions, if a prior neurological or psychiatric condition was present they must have returned to normal
- No cognitive complaints
- Normal neurological examination
- No psychoactive medications
- They may have a chronic medical condition that does not affect cognition
- Low Aβ load Pittsburgh compound-B (PiB) ratio \<1.5
- Inclusion Criteria for Mild Cognitive Impairment Subjects:
- In good general health
- Memory complaint documented by the patient and collateral source
- Normal general cognitive function as determined by measure of general intellectual function and screening including the Short Test of Mental Status
- Normal activities of daily living as documented by history and Record of Independent Living
- Not demented by DSM-III-R criteria
- Do have an objective memory impairment determined by the clinical judgement of the neuropsychologists and neurologists
- High Aβ load Pittsburgh compound-B (PiB) ratio ≥1.5
- Inclusion Criteria for Alzheimer's Disease Subjects:
- In good general health
- Dementia not a result of other medical or psychiatric conditions
- Diagnosis of dementia made according to DSM-III-R criteria
- Do have objective memory impairment determined by the clinical judgement of the neuropsychologists and neurologists
- High Aβ load Pittsburgh compound-B (PiB) ratio ≥1.5
- Exclusion Criteria:
- Alzheimer's disease or mild cognitive impairment due to a known genetic mutation
- Major depression
- History of primary or metastatic intracranial neoplasm, significant head trauma, intra-cerebral hemorrhage, hemispheric stroke
- Contradictions to MRI imaging including but not limited to cardiac pacemakers, intraocular or intracranial metal, or other MRI incompatible devices.
- Pregnant women. Women of child bearing potential will be given a urine pregnancy test prior the MRI scan. Results will be shared with the participant. If the pregnancy test is positive, the participant will not be included within the study
Exclusion
Key Trial Info
Start Date :
October 11 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 1 2027
Estimated Enrollment :
450 Patients enrolled
Trial Details
Trial ID
NCT06029114
Start Date
October 11 2023
End Date
November 1 2027
Last Update
December 24 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic Minnesota
Rochester, Minnesota, United States, 55905